Global Tildrakizumab Market Size By Type (18MIU /Vial, 25MIU /Vial), By Application (Hospital, Drug Store), By Region, And Segment Forecasts, 2023 to 2032

The Global Tildrakizumab Market was valued at USD 612 million in 2023 and is projected to reach USD 1.54 billion by 2031, growing at a CAGR of 12.3% during the forecast period from 2023 to 2031. Tildrakizumab, a monoclonal antibody targeting interleukin-23 (IL-23), is used primarily for the treatment of moderate-to-severe plaque psoriasis and is showing promise in other inflammatory disorders. Market growth is fueled by the rising prevalence of psoriasis, increasing acceptance of biologic therapies, and ongoing clinical developments for expanded indications.

Drivers:

Rising Psoriasis Incidence:

The global burden of plaque psoriasis is increasing, affecting over 2% of the world’s population. This growing patient base fuels demand for effective, long-lasting biologic treatments like Tildrakizumab.

Preference for Targeted Biologics:

Biologics targeting IL-23 offer better tolerability and efficacy than traditional systemic therapies. Tildrakizumab, with its quarterly dosing and high patient adherence, is emerging as a preferred therapy.

Expanding Clinical Pipeline:

Ongoing research for Tildrakizumab's application in other autoimmune and inflammatory conditions—such as psoriatic arthritis and Crohn’s disease—is opening new growth avenues.

Restraints:

High Cost of Biologic Therapy:

The premium pricing of monoclonal antibodies like Tildrakizumab poses affordability challenges in developing countries, limiting broader access.

Competition from Alternative Biologics:

The market faces stiff competition from established biologics like Secukinumab, Ustekinumab, and newer IL-17/IL-23 inhibitors, potentially impacting market share.

Opportunity:

Biosimilar Development:

As patent expiration looms in the late forecast period, the introduction of biosimilars presents opportunities for market expansion in cost-sensitive regions.

Emerging Markets Penetration:

Improved healthcare infrastructure, reimbursement frameworks, and growing awareness in Asia-Pacific and Latin America offer untapped growth potential.

Market by System Type Insights:

The market is segmented by formulation type into Subcutaneous and Intravenous. Subcutaneous administration dominated in 2023, driven by the convenience of at-home dosing and patient preference for self-injection. The segment is expected to maintain its lead, supported by improved delivery devices and minimal training requirements.

Market by End-Use Insights:

By end-use, the market is segmented into Hospitals, Specialty Clinics, and Homecare Settings. Hospitals accounted for the largest share in 2023 due to initial treatment and biologic initiation protocols. However, Homecare Settings are expected to grow the fastest due to the trend of decentralized care and chronic disease management at home.

Market by Regional Insights:

North America dominated the Tildrakizumab market in 2023, owing to high diagnosis rates, advanced reimbursement frameworks, and strong penetration of biologic therapies. Europe followed closely with robust adoption across key markets like Germany and the UK. Asia-Pacific is forecasted to witness the highest CAGR, driven by rising healthcare investments and expanding access to advanced treatments.

Competitive Scenario:

Key players in the global Tildrakizumab market include Sun Pharmaceutical Industries Ltd., Merck & Co., Inc. (original developer), Biocon Biologics, Dr. Reddy’s Laboratories, and potential biosimilar developers. Strategic initiatives like geographic expansion, new indication approvals, and lifecycle management strategies are prominent. For instance:

Sun Pharma announced real-world evidence data supporting the long-term efficacy of Tildrakizumab in 2024.

Biocon Biologics initiated biosimilar development programs aimed at launching post-patent expiry by 2030.

Scope of Work – Global Tildrakizumab Market

Key Market Developments:

2024: Sun Pharmaceutical Industries published new clinical outcomes highlighting sustained PASI-90 response over 52 weeks.

2023: Biocon Biologics initiated pre-clinical trials for a Tildrakizumab biosimilar aimed at regulated markets.

2023: Regulatory discussions progressed in the EU regarding expanded indications for inflammatory bowel diseases.

FAQs:

1) What is the current market size of the Global Tildrakizumab Market?

The market size was valued at USD 612 million in 2023.

2) What is the major growth driver of the Global Tildrakizumab Market?

Rising prevalence of psoriasis and increased adoption of biologic therapies are key growth drivers.

3) Which is the largest region during the forecast period in the Global Tildrakizumab Market?

North America is the largest region due to high biologic adoption and favorable healthcare infrastructure.

4) Which segment accounted for the largest market share in the Global Tildrakizumab Market?

The Subcutaneous formulation segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Tildrakizumab Market?

Key players include Sun Pharmaceutical Industries Ltd., Biocon Biologics, and other emerging biosimilar developers.